Patient-reported outcome measures in functional dyspepsia: a systematic review and COSMIN analysis.

Dyspepsia Functional dyspepsia Measurement properties Patient-reported outcome measure

Journal

BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547

Informations de publication

Date de publication:
19 Sep 2023
Historique:
received: 20 02 2023
accepted: 26 08 2023
medline: 21 9 2023
pubmed: 20 9 2023
entrez: 19 9 2023
Statut: epublish

Résumé

Functional dyspepsia (FD) as a type of disorders of brain-gut interaction (DBGI), patient self-reporting of its symptoms becomes an important component of clinical outcome assessment. We performed a systematic review using Consensus Based Standards for the Selection of Health Measurement Instruments (COSMIN) guidelines to identify the best available patient-reported outcome measure (PROM) of FD. The study was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). We searched four databases with no date limit, looking for previously confirmed PROMs for evaluating FD symptoms. An overall rating was then assigned based upon COSMIN guidelines, and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach was used to assess the level of evidence for psychometric properties of included PROMs. Thirty articles covering outcome indicators of 24 patient reports were included. The Leuven Postprandial Distress Scale (LPDS) showed adequate content validity and moderate quality evidence of adequate internal consistency to generate an A recommendation. LPDS is currently the most recommended PROM for patient self-reported FD symptoms. However, it fails to assess two important areas of cross-cultural validity/ measurement invariance and measurement error. Future research can be continuously improved on this basis.

Sections du résumé

BACKGROUND BACKGROUND
Functional dyspepsia (FD) as a type of disorders of brain-gut interaction (DBGI), patient self-reporting of its symptoms becomes an important component of clinical outcome assessment. We performed a systematic review using Consensus Based Standards for the Selection of Health Measurement Instruments (COSMIN) guidelines to identify the best available patient-reported outcome measure (PROM) of FD.
METHODS METHODS
The study was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). We searched four databases with no date limit, looking for previously confirmed PROMs for evaluating FD symptoms. An overall rating was then assigned based upon COSMIN guidelines, and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach was used to assess the level of evidence for psychometric properties of included PROMs.
RESULTS RESULTS
Thirty articles covering outcome indicators of 24 patient reports were included. The Leuven Postprandial Distress Scale (LPDS) showed adequate content validity and moderate quality evidence of adequate internal consistency to generate an A recommendation.
CONCLUSION CONCLUSIONS
LPDS is currently the most recommended PROM for patient self-reported FD symptoms. However, it fails to assess two important areas of cross-cultural validity/ measurement invariance and measurement error. Future research can be continuously improved on this basis.

Identifiants

pubmed: 37726672
doi: 10.1186/s12876-023-02935-9
pii: 10.1186/s12876-023-02935-9
pmc: PMC10507973
doi:

Types de publication

Systematic Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

316

Informations de copyright

© 2023. BioMed Central Ltd., part of Springer Nature.

Références

Drossman DA, Tack J, Ford AC, et al. Neuromodulators for Functional Gastrointestinal Disorders (Disorders of Gut-Brain Interaction): A Rome Foundation Working Team Report. Gastroenterology. 2018;154(4):1140-1171.e1.
pubmed: 29274869 doi: 10.1053/j.gastro.2017.11.279
Wauters L, Dickman R, Drug V, et al. United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on functional dyspepsia. United European Gastroenterology J. 2021;9(3):307–31.
doi: 10.1002/ueg2.12061
Taylor F, Reasner DS, Carson RT, et al. Development of a symptom-based patient-reported outcome instrument for functional dyspepsia: a preliminary conceptual model and an evaluation of the adequacy of existing instruments. Patient. 2016;9(5):409–18.
pubmed: 27020447 pmcid: 5021747 doi: 10.1007/s40271-016-0164-1
Ford AC, Mahadeva S, Carbone MF, et al. Functional dyspepsia. Lancet. 2020;396(10263):1689–702.
pubmed: 33049222 doi: 10.1016/S0140-6736(20)30469-4
Mahadeva S, Ford AC. Clinical and epidemiological differences in functional dyspepsia between the East and the West. Neurogastroenterol Motil. 2016;28(2):167–74.
pubmed: 26331919 doi: 10.1111/nmo.12657
Aziz I, Palsson OS, Törnblom H, et al. Epidemiology, clinical characteristics, and associations for symptom-based Rome IV functional dyspepsia in adults in the USA, Canada, and the UK: a cross-sectional population-based study. Lancet Gastroenterol Hepatol. 2018;3(4):252–62.
pubmed: 29396034 doi: 10.1016/S2468-1253(18)30003-7
Gubatan J, Zikos T, Spear Bishop E, et al. Gastrointestinal symptoms and healthcare utilization have increased among patients with functional gastrointestinal and motility disorders during the COVID-19 pandemic[J]. Neurogastroenterol Motil. 2022;34(4):e14243.
Sayuk GS, Gyawali CP. Functional dyspepsia: diagnostic and therapeutic approaches. Drugs. 2020;80(13):1319–36.
pubmed: 32691294 doi: 10.1007/s40265-020-01362-4
Ford AC, Moayyedi P, Black CJ, et al. Systematic review and network meta-analysis: efficacy of drugs for functional dyspepsia. Aliment Pharmacol Ther. 2021;53(1):8–21.
pubmed: 32936964 doi: 10.1111/apt.16072
Madisch A, Andresen V, Enck P, et al. The diagnosis and treatment of functional dyspepsia. Dtsch Arztebl Int. 2018;115(13):222–32.
pubmed: 29669681 pmcid: 5938438
Masuy I, Van Oudenhove L, Tack J. Review article: treatment options for functional dyspepsia. Aliment Pharmacol Ther. 2019;49(9):1134–72.
pubmed: 30924176 doi: 10.1111/apt.15191
Miwa H, Nagahara A, Asakawa A, et al. Evidence-based clinical practice guidelines for functional dyspepsia 2021. J Gastroenterol. 2022;57(2):47–61.
pubmed: 35061057 pmcid: 8831363 doi: 10.1007/s00535-021-01843-7
Wauters L, Talley NJ, Walker MM, et al. Novel concepts in the pathophysiology and treatment of functional dyspepsia. Gut. 2020;69(3):591–600.
pubmed: 31784469 doi: 10.1136/gutjnl-2019-318536
Guidance for industry. patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes. 2006;4:79.
doi: 10.1186/1477-7525-4-79
Smeets FGM, Masclee AAM, Conchillo JM, et al. Systematic review: disease‐specific instruments to assess gastrointestinal symptoms in functional dyspepsia[J]. Neurogastroenterol Motil. 2018;30(8):e13327.
Prinsen CAC, Mokkink LB, Bouter LM, et al. COSMIN guideline for systematic reviews of patient-reported outcome measures[J]. Qual Life Res. 2018;27(5):1147–57.
pubmed: 29435801 pmcid: 5891568 doi: 10.1007/s11136-018-1798-3
Alhazzani W, Guyatt G. An overview of the GRADE approach and a peek at the future. Med J Aust. 2018;209(7):291–2.
pubmed: 30257627 doi: 10.5694/mja18.00012
Mokkink LB, De Vet HCW, Prinsen CAC, et al. COSMIN Risk of Bias checklist for systematic reviews of Patient-Reported Outcome Measures. Qual Life Res. 2018;27(5):1171–9.
pubmed: 29260445 doi: 10.1007/s11136-017-1765-4
Terwee CB, Bot SD, De Boer MR, et al. Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol. 2007;60(1):34–42.
pubmed: 17161752 doi: 10.1016/j.jclinepi.2006.03.012
Svedlund J, Sjödin I, Dotevall G. GSRS–a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci. 1988;33(2):129–34.
pubmed: 3123181 doi: 10.1007/BF01535722
Kulich KR, Madisch A, Pacini F, et al. Reliability and validity of the Gastrointestinal Symptom Rating Scale (GSRS) and Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire in dyspepsia: A six-country study. Health Qual Life Outcomes. 2008;6:12.
pubmed: 18237386 pmcid: 2276197 doi: 10.1186/1477-7525-6-12
El-Omar EM, Banerjee S, Wirz A, et al. The glasgow dyspepsia severity score - a tool for the global measurement of dyspepsia. Eur J Gastroenterol Hepatol. 1996;8(10):967–71.
pubmed: 8930560 doi: 10.1097/00042737-199610000-00006
Garratt AM, Ruta DA, Russell I, et al. Developing a condition-specific measure of health for patients with dyspepsia and ulcer-related symptoms. J Clin Epidemiol. 1996;49(5):565–71.
pubmed: 8636730 doi: 10.1016/0895-4356(95)00584-6
Moayyedi P, Duffett S, Braunholtz D, et al. The Leeds Dyspepsia Questionnaire: a valid tool for measuring the presence and severity of dyspepsia. Am J Gastroenterol. 1998;12(12):1257–62.
Shaw M, Talley NJ, Adlis S, et al. Development of a digestive health status instrument: tests of scaling assumptions, structure and reliability in a primary care population. Aliment Pharmacol Ther. 1998;12(11):1067–78.
pubmed: 9845396 doi: 10.1046/j.1365-2036.1998.00399.x
Shaw MJ, Beebe TJ, Adlis SA, et al. Reliability and validity of the digestive health status instrument in samples of community, primary care, and gastroenterology patients. Aliment Pharmacol Ther. 2001;15(7):981–7.
pubmed: 11421873 doi: 10.1046/j.1365-2036.2001.01026.x
Talley NJ, Haque M, Wyeth JW, et al. Development of a new dyspepsia impact scale: the Nepean Dyspepsia Index. Aliment Pharmacol Ther. 1999;13(2):225–35.
pubmed: 10102954 doi: 10.1046/j.1365-2036.1999.00445.x
Leidy NK, Farup C, Rentz AM, et al. Patient-based assessment in dyspepsia - Development and validation of Dyspepsia Symptom Severity Index (DSSI). Dig Dis Sci. 2000;45(6):1172–9.
pubmed: 10877234 doi: 10.1023/A:1005558204440
Rabeneck L, Cook KF, Wristers K, et al. SODA (severity of dyspepsia assessment): a new effective outcome measure for dyspepsia-related health. J Clin Epidemiol. 2001;54(8):755–65.
pubmed: 11470383 doi: 10.1016/S0895-4356(00)00365-6
Goldman J, Conrad DF, Ley C, et al. Validation of Spanish Language Dyspepsia Questionnaire. Dig Dis Sci. 2002;47(3):624–40.
pubmed: 11913412 doi: 10.1023/A:1017936623783
Hu WHC, Lam KF, Wong YH, et al. The Hong Kong index of dyspepsia: A validated symptom severity questionnaire for patients with dyspepsia. J Gastroenterol Hepatol (Australia). 2002;17(5):545–51.
doi: 10.1046/j.1440-1746.2002.02713.x
Sander GB, Mazzoleni LE, Francesconi CFM, et al. Development and validation of a cross-cultural questionnaire to evaluate nonulcer dyspepsia: The Porto Alegre Dyspeptic Symptoms Questionnaire (PADYQ). Dig Dis Sci. 2004;49(11–12):1822–9.
pubmed: 15628711 doi: 10.1007/s10620-004-9578-z
Rentz AM, Kahrilas P, Stanghellini V, et al. Development and psychometric evaluation of the patient assessment of upper gastrointestinal symptom severity index (PAGI-SYM) in patients with upper gastrointestinal disorders. Qual Life Res. 2004;13(10):1737–49.
pubmed: 15651544 doi: 10.1007/s11136-004-9567-x
Revicki DA, Rentz AM, Tack J, et al. Responsiveness and interpretation of a symptom severity index specific to upper gastrointestinal disorders. Clin Gastroenterol Hepatol. 2004;2(9):769–77.
pubmed: 15354277 doi: 10.1016/S1542-3565(04)00348-9
De Luca L, Zagari RM, Pozzato P, et al. Measuring dyspepsia: A new severity index validated in Bologna. Dig Liver Dis. 2004;36(12):806–10.
pubmed: 15646426 doi: 10.1016/j.dld.2004.07.010
Adam B, Liebregts T, Saadat-Gilani K, et al. Validation of the gastrointestinal symptom score for the assessment of symptoms in patients with functional dyspepsia. Aliment Pharmacol Ther. 2005;22(4):357–63.
pubmed: 16098003 doi: 10.1111/j.1365-2036.2005.02572.x
Veldhuyzen Van Zanten SJ, Chiba N, Armstrong D, et al. Validation of a 7-point Global Overall Symptom scale to measure the severity of dyspepsia symptoms in clinical trials. Aliment Pharmacol Ther. 2006;23(4):521–9.
pubmed: 16441473 doi: 10.1111/j.1365-2036.2006.02774.x
Fraser A, Delaney BC, Ford AC, et al. The Short-Form Leeds Dyspepsia Questionnaire validation study. Aliment Pharmacol Ther. 2007;25(4):477–86.
pubmed: 17270004 doi: 10.1111/j.1365-2036.2006.03233.x
Crowell MD, Umar SB, Lacy BE, et al. Multi-Dimensional Gastrointestinal Symptom Severity Index: Validation of a Brief GI Symptom Assessment Tool. Dig Dis Sci. 2015;60(8):2270–9.
pubmed: 25842355 doi: 10.1007/s10620-015-3647-3
Carbone F, Vandenberghe A, Holvoet L, et al. Validation of the Leuven Postprandial Distress Scale, a questionnaire for symptom assessment in the functional dyspepsia/postprandial distress syndrome. Aliment Pharmacol Ther. 2016;44(9):989–1001.
pubmed: 27518319 doi: 10.1111/apt.13753
Carbone F, Holvoet L, Vandenberghe A, et al. Functional dyspepsia: outcome of focus groups for the development of a questionnaire for symptom assessment in patients suffering from postprandial distress syndrome (PDS). Neurogastroenterol Motil. 2014;26(9):1266–74.
pubmed: 25130784 doi: 10.1111/nmo.12381
Taylor F, Higgins S, Carson RT, et al. Development of a Symptom-Focused Patient-Reported Outcome Measure for Functional Dyspepsia: The Functional Dyspepsia Symptom Diary (FDSD). Am J Gastroenterol. 2018;113(1):39–48.
pubmed: 28925989 doi: 10.1038/ajg.2017.265
Shi X, Luo H, Wang X, et al. Functional dyspepsia symptom diary is correlated with other questionnaires and associated with severity in patients with functional dyspepsia: a multicenter, prospective observational study. J Gastroenterol Hepatol. 2022;37:1298–306.
pubmed: 35434810 doi: 10.1111/jgh.15854
Koloski NA, Jones M, Hammer J, et al. The Validity of a New Structured Assessment of Gastrointestinal Symptoms Scale (SAGIS) for Evaluating Symptoms in the Clinical Setting. Dig Dis Sci. 2017;62(8):1913–22.
pubmed: 28551709 doi: 10.1007/s10620-017-4599-6
Smeets FGM, Keszthelyi D, Vork L, et al. Development of a real-time patient-reported outcome measure for symptom assessment in patients with functional dyspepsia using the experience sampling method[J]. Neurogastroenterol Motil. 2019;31(2):e13496.
pubmed: 30393939 doi: 10.1111/nmo.13496
Klaassen T, Smeets FGM, Vork L, et al. Psychometric evaluation of an experience sampling method-based patient-reported outcome measure in functional dyspepsia[J]. Neurogastroenterol Motil. 2021;33(9):e14136.
pubmed: 33934444 pmcid: 8519073 doi: 10.1111/nmo.14136
Chan Y, Cheong PK, Fang FF, et al. A symptom severity questionnaire for patients suffering from functional gastrointestinal disorder: FGI-Checklist. J Gastroenterol Hepatol. 2020;35(7):1130–5.
pubmed: 31734958 doi: 10.1111/jgh.14937
Xiao M, Ying J, Zhao Y, et al. Developing a Scale for the Evaluation of People With Post-prandial Distress Syndrome. Front Public Health. 2021;9:695809.
pubmed: 34268292 pmcid: 8275927 doi: 10.3389/fpubh.2021.695809
Jung K, Jung H-K, Kwon JG, et al. Development and Validity Assessment of a Self-evaluation Questionnaire for Functional Dyspepsia: A Multicenter Prospective Study in Korea. J Neurogastroenterol Motil. 2022;28(1):111–20.
pubmed: 34980694 pmcid: 8748857 doi: 10.5056/jnm20250
Jones M, Talley NJ. Minimum clinically important difference for the Nepean Dyspepsia Index, a validated quality of life scale for functional dyspepsia. Am J Gastroenterol. 2009;104(6):1483–8.
pubmed: 19491862 doi: 10.1038/ajg.2009.136
Jones MP, Sato YA, Talley NJ. The Nepean Dyspepsia Index is a valid instrument for measuring quality-of-life in functional dyspepsia. Eur J Gastroenterol Hepatol. 2019;31(3):329–33.
pubmed: 30461521 doi: 10.1097/MEG.0000000000001314
Mahadeva S, Wee H-L, Goh K-L, et al. Quality of life in South East Asian patients who consult for dyspepsia: Validation of the short form Nepean Dyspepsia Index[J]. Health and Quality of Life Outcomes. 2009;7:45.
pubmed: 19463190 pmcid: 2693522 doi: 10.1186/1477-7525-7-45
Ioannidis JP, Greenland S, Hlatky MA, et al. Increasing value and reducing waste in research design, conduct, and analysis. Lancet. 2014;383(9912):166–75.
pubmed: 24411645 pmcid: 4697939 doi: 10.1016/S0140-6736(13)62227-8
Bastiaansen JA, Meurs M, Stelwagen R, et al. Self-monitoring and personalized feedback based on the experiencing sampling method as a tool to boost depression treatment: a protocol of a pragmatic randomized controlled trial (ZELF-i). BMC Psychiatry. 2018;18(1):276.
pubmed: 30176845 pmcid: 6122175 doi: 10.1186/s12888-018-1847-z
Riese H, Von Klipstein L, Schoevers RA, et al. Personalized ESM monitoring and feedback to support psychological treatment for depression: a pragmatic randomized controlled trial (Therap-i). BMC Psychiatry. 2021;21(1):143.
pubmed: 33691647 pmcid: 7945664 doi: 10.1186/s12888-021-03123-3
Van Os J, Verhagen S, Marsman A, et al. The experience sampling method as an mHealth tool to support self-monitoring, self-insight, and personalized health care in clinical practice. Depress Anxiety. 2017;34(6):481–93.
pubmed: 28544391 doi: 10.1002/da.22647
Tack J, Carbone F, Holvoet L, et al. The use of pictograms improves symptom evaluation by patients with functional dyspepsia. Aliment Pharmacol Ther. 2014;40(5):523–30.
pubmed: 25052080 doi: 10.1111/apt.12855

Auteurs

Xinai Wang (X)

The School of Graduate, Tianjin University of Traditional Chinese Medicine, Tianjin, China.

Yan Fei (Y)

Shanghai Tenth People's Hospital Chongming Branch, Shanghai, China.

Wenjing Li (W)

The School of Graduate, Tianjin University of Traditional Chinese Medicine, Tianjin, China.

Hao Liu (H)

The School of Graduate, Tianjin University of Traditional Chinese Medicine, Tianjin, China.

Hongling Xiao (H)

The School of Nursing, Tianjin University of Traditional Chinese Medicine, Tianjin, China. dingxiyuan303@sina.com.

Yaxuan Wu (Y)

The School of Graduate, Tianjin University of Traditional Chinese Medicine, Tianjin, China.

Chenqi Wang (C)

The School of Graduate, Tianjin University of Traditional Chinese Medicine, Tianjin, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH